智通财经网·2025-08-26 12:37Core Insights - The company reported a revenue of approximately 669 million, representing a year-on-year decrease of 21.3% [1] - Gross profit was about 105 million, down 50.3% year-on-year [1] - Net profit was 60.93 million, marking a turnaround from a loss to profit [1] - Earnings per share stood at 0.08 [1] Revenue and Profit Analysis - The decline in revenue is primarily attributed to intensified competition leading to a decrease in project unit prices [1] - The increase in net profit is mainly due to changes in the fair value of biological assets [1] - The company recognized a gain of 95 million from the fair value changes of biological assets during the period [1] Biological Assets Performance - For the six months ending June 30, 2025, the gains from biological assets were driven by natural growth [1] - In contrast, for the six months ending June 30, 2024, the company reported a loss of 254.4 million, primarily due to a decrease in the unit fair value of biological assets, consistent with the decline in market prices of experimental models [1]